Identifying Cancer Relapse Using Seer-Medicare Data

INTRODUCTION: Tumor registries capture valid information at the time of cancer diagnosis, but often do not conduct longitudinal follow-up evaluations. However, investigators may be interested in questions relating to subsequent relapsed disease. Linking administrative data to registry data, as in the creation of the SEER (Surveillance, Epidemiology, and End Results) and Medicare data set, can provide the ability to infer the occurrence of relapse in selected situations. METHODS: The authors created different algorithms to detect relapse of acute myelogenous leukemia (AML). A retrospective cohort of patients with AML was identified, and both their billing data and medical records were obtained. The algorithms were then applied to the billing data, the results were compared with medical record review. RESULTS: Eighty-nine patients were identified, of whom 22 were treated for relapsed AML. The sensitivity of the best algorithm for detecting relapse was 86%, and the specificity 99%, with a positive predictive value of 95% and a negative predictive value of 96%. CONCLUSIONS: Identification of relapse from SEER-Medicare data using clinical algorithms is feasible for cancers where a majority of patients receive treatment for relapse, without a "watch and wait" strategy, and where that treatment is with a modality that can be detected in billing data (ie, intravenous chemotherapy, radiation, surgery, or all three). Optimal analytic situations are ones in which the investigator is mostly interested in positive predictive value, less interested in sensitivity, and wants to evaluate outcomes among those patients who receive treatment for their relapsed disease. However, the accuracy of such an approach for cancers other than AML has not yet been established

Cancer · Cancer registry · Cohort · Diagnosis code · Disease · Family medicine · Medical record · Population · Predictive value · Retrospective cohort study · Surveillance, Epidemiology, and End Results · Acute Lymphoblastic Leukemia research · Acute Myeloid Leukemia Research · Chronic Myeloid Leukemia Treatments · Epidemiology · Internal Medicine · Medicine · Oncology

• Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management

  Michael J Hassett, Hajime Uno et al.•Medical Care•2017

  Incluir item

• Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients

  Joan L Warren, Ângela Mariotto et al.•Medical Care•2016

  Incluir item

• Overview of the Seer-Medicare Data

  Joan L Warren, Carrie N Klabunde et al.•Medical Care•2002

  Incluir item

• Methodological Issues in the Use of Administrative Claims Data to Study Surveillance After Cancer Treatment

  Ann B Nattinger, Marilyn M Schapira et al.•Medical Care•2002

  Incluir item

• An Electronic Health Record–based Algorithm to Ascertain the Date of Second Breast Cancer Events

  Jessica Chubak, Tracy Onega et al.•Medical Care•2017

  Incluir item

• A Hybrid Approach to Identify Subsequent Breast Cancer Using Pathology and Automated Health Information Data

  Reina Haque, Jiaxiao Shi et al.•Medical Care•2015

  Incluir item

• Validity of Administrative Data in Identifying Cancer-related Events in Adolescents and Young Adults

  Sumit Gupta, Paul C Nathan et al.•Medical Care•2018

  Incluir item

• Impact of Individual and Market Factors on the Timing of Initiation of Hospice Terminal Care

  Nicholas A Christakis, Theodore J Iwashyna•Medical Care•2000

  Incluir item